免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展

doi:10.16352/j.issn.1001-6325.2023.07.1143

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1143-1147.doi: 10.16352/j.issn.1001-6325.2023.07.1143

免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展

陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静^*

杭州医学院检验医学院、生物工程学院,浙江杭州 310053

收稿日期:2022-08-20 修回日期:2023-03-16 出版日期:2023-07-05 发布日期:2023-07-05
通讯作者: ^*jiajingzjams@163.com
基金资助:
国家自然科学基金(81802622); 浙江省自然科学基金(LY18H160067)

Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development

CHEN Zhongjie, HUANG Jiaru, HU Qing, ZHAO Zhenqin, CHEN Qiaoqiao, SUN Junyuan, JIA Jing^*

School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou 310053, China

Received:2022-08-20 Revised:2023-03-16 Online:2023-07-05 Published:2023-07-05

摘要/Abstract

摘要： 免疫检查点CD276,B7分子家族成员,可与磷脂酰肌醇3激酶/蛋白激酶B(PI3K/AKT)等信号通路相互作用,调控肿瘤能量代谢,抑制免疫细胞抗肿瘤活性,促肿瘤血管新生,帮助肿瘤免疫逃逸与肿瘤转移。CD276与肿瘤干性及化学治疗耐药密切相关。迄今若干以CD276为靶点的抗体类药物及细胞治疗方法已经进入临床试验。CD276还可作为肿瘤标志物用于肿瘤的诊断和分型。CD276的调控机制有非编码RNA、转录因子介导的转录水平调控,甲基化、糖基化等介导的翻译后修饰水平调控。

关键词: CD276, 肿瘤免疫逃逸, 肿瘤病理机制, 肿瘤免疫治疗, 免疫检查点

Abstract: The immune checkpoint CD276 protein, belonging to the B7 family molecules, could interact with important signaling pathways, such as phosphatidylinositol 3 kinase/protein kinase B(PI3K/AKT)signaling pathway, resulting to the regulation of tumor energy metabolism, inhibition of the anti-tumor activity of immune cells, promotion of tumor angiogenesis, and the assistance of tumor immune escape and metastasis. CD276 also potentially related to tumor stemness and chemotherapy resistance closely. Several antibody drugs and cell therapy methods targeting at CD276 have been proved in clinical trials. CD276 can also be used as a biomarker for tumor diagnosis and subtyping. The upstream regulatory mechanisms of CD276 include transcriptional level regulation mediated by non-coding RNA and transcription factors, and post-translational modification level regulation mediated by methylation and glycosylation.

Key words: CD276, tumor immune escape, tumor pathological mechanism, tumor immunotherapy, immune checkpoint

中图分类号:

R730.3

陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.

CHEN Zhongjie, HUANG Jiaru, HU Qing, ZHAO Zhenqin, CHEN Qiaoqiao, SUN Junyuan, JIA Jing. Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development[J]. Basic & Clinical Medicine, 2023, 43(7): 1143-1147.

参考文献

[1] Shao L, Yu Q, Xia R,et al. B7-H3 on breast cancer cell MCF7 inhibits IFN-gamma release from tumour-infiltrating T cells[J]. Pathol Res Pract, 2021, 224:153461.doi:10.1016./j.prp.2021.153461.
[2] Wang C, Li Y, Jia L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance[J]. Cell Stem Cell, 2021, 28:1597-1613.
[3] Miyamoto T, Murakami R, Hamanishi J, et al. B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression[J]. Cancer Immunol Res, 2022, 10:56-69.
[4] Aggarwal C, Prawira A, Antonia S, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial[J]. J Immunother Cancer, 2022,10:e004424.doi: 10.1136/jitc-2021-004424.
[5] Wang J, Chen X, Xie C, et al. MicroRNA miR-29a inhibits colon cancer progression by downregulating B7-H3 expression: potential molecular targets for colon cancer therapy[J]. Mol Biotechnol, 2021,63:849-861.
[6] Liao H, Ding M, Zhou N, et al. B7H3 promotes the epithelialmesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway[J]. Mol Med Rep, 2022, 25:79.doi: 10.3892/mmr.2022.12595.
[7] Wang S, Zhang X, Ning H, et al. B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis[J]. Breast Cancer Res Treat, 2022, 193:405-416.
[8] Qin F, Lin S, Deng K, et al. Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma[J]. World J Surg Oncol, 2021, 19:275.doi: 10.1186/s12957-021-02367-3.
[9] Wang R, Ma Y, Zhan S, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression[J]. Cell Death Dis, 2020, 11:55.doi: 10.1038/s41419-020-2252-3.
[10] Cheng N, Bei Y, Song Y, et al. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy[J]. Biochem Pharmacol, 2021, 183:114298. doi: 10.1016/j.bcp.2020.114298.
[11] Yue G, Tang J, Zhang L, et al. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma[J]. J Gastrointest Oncol, 2021,12:38-51.
[12] Picarda E, Galbo PM, Zong H,et al. The immune checkpoint B7-H3. The immune checkpoint B7-H3 (CD276) regulates adipocyte progeni-tor metabolism and obesity development[J]. Sci Adv, 2022, 8:eabm7012.doi: 10.1126/sciadv.abm7012.
[13] Huang Z, Li Y, Hong W, et al. Identification of a ferroptosis-associated gene signature and the related therapeutic targets in head and neck squamous carcinoma[J]. Int Immunopharmacol, 2022, 102:108431.doi: 10.1016/j.intimp.2021.108431.
[14] Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer[J]. NPJ Precis Oncol, 2022, 6:80.doi: 10.1038/s41698-022-00323-2.
[15] Amori G, Sugawara E, Shigematsu Y, et al. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer[J]. Prostate Cancer Prostatic Dis, 2021, 24:767-774.
[16] Gao Q, Cui L, Huang C, et al. Gastric cancer-derived mesenchymal stem cells promote gastric cancer cell lines migration by modulating CD276 expression[J]. Exp Cell Res, 2022, 422:113414.doi: 10.1016/j.yexcr.2022.113414.
[17] Zhang Y, He L, Sadagopan A, et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR-T cells[J]. Mol Cancer Ther, 2021,20:577-588.
[18] Bachawal S, Bean GR, Krings G, et al. Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression[J]. NPJ Breast Cancer, 2020,6:14.doi:10.1038/s41523-020-0158-y.
[19] Zhao S, Wang Y, Yang N, et al. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells[J]. J Immunother Cancer, 2022, 10:e004875.doi:10.1136.
[20] Kramer K, Pandit-Taskar N, Kushner BH, et al. Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies[J]. J Hematol Oncol, 2022, 15:165.doi: 10.1186/s13045-022-01383-4.
[21] Vitanza NA, Wilson AL, Huang W, et al. Intraventri-cular B7-H3 CAR-T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety[J]. Cancer Discov, 2023, 13:114-131.
[22] Lichtman EI, Du H, Shou P, et al. Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2021, 27:3141-3153.
[23] Grote S, Urena-Bailen G, Chan KC, et al. In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment[J]. Cells, 2021, 10:1020.doi: 10.3390/cells10051020.
[24] Urena-Bailen G, Dobrowolski JM, Hou Y, et al. Preclinical evaluation of CRISPR-Edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL[J]. Int J Mol Sci, 2022, 23:12828.doi: 10.3390/ijms232112828.

免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展

Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[2]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[3]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[4]	甘兹颖, 唐慧. 溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展[J]. 基础医学与临床, 2022, 42(4): 651-655.
[5]	斯晓燕, 王汉萍, 张力, 王孟昭, 张晓彤. 免疫检查点抑制剂致细胞因子释放综合征1例[J]. 基础医学与临床, 2022, 42(11): 1764-1766.
[6]	张若曦, 韩冰. 免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展[J]. 基础医学与临床, 2021, 41(8): 1210-1215.
[7]	李佳忆, 幸兵. 免疫检查点抑制剂相关自身免疫性垂体炎的研究进展[J]. 基础医学与临床, 2020, 40(3): 403-406.